To compare the efficacy and safety of nifedipine sustained release with Ginkgo biloba extract to treat patients with primary Raynaud's phenomenon in South Korea; Korean Raynaud study (KOARA study)

Clinical Rheumatology

Volumn 28, Issue 5, 2009, Pages 553-559

  Choi, Whan Seok ^a   Choi, Chang Jin ^a   Kim, Kyung Soo ^a   Lee, Jae Ho ^a   Song, Chan Hee ^a   Chung, Ju Hye ^a   Ock, Sun Myeoung ^a   Lee, Jung Bok ^b   Kim, Chul Min ^a  

^a The Catholic University of Korea   (South Korea)

^b Korea University   (South Korea)

Author keywords

Ginkgo; Ginkgo biloba extract; Nifedipine; Nifedipine sustained release; Primary Raynaud's phenomenon; Raynaud's phenomenon

Indexed keywords

GINKGO BILOBA EXTRACT; NIFEDIPINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; SOUTH KOREA; SUSTAINED RELEASE FORMULATION; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; DELAYED-ACTION PREPARATIONS; FEMALE; GINKGO BILOBA; HUMANS; KOREA; MALE; MIDDLE AGED; NIFEDIPINE; PHYTOTHERAPY; PLANT EXTRACTS; RAYNAUD DISEASE; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 64449085964     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-008-1084-9     Document Type: Article

References (26)

1. Raynaud M (1864) On local asphyxia and symmetrical gangrene of extremities. Selected Monographs. New Sydenham Society, London, p 1888
2. Porter JM, Rivers SP, Anderson CJ, Baur GM (1981) Evaluation and management of patients with Raynaud's Syndrome. Am J Surg 142:183-89
3. Wigley FM (2002) Raynaud's phenomenon. N Engl J Med 347:1001-1008
4. Walker DD, Jones B, Ogston S, Tasker EG, Robinson AJ (1985) A study of white finger in the gas industry. Br J Ind Med 42:672-677
5. Leppert J, Aberg H, Rinqvist I, Sorensson S (1987) Raynaud's phenomenon in a female population: Prevalence and association with other conditions. Angiology 38:871-877
6. Keil JE, Maricq HR, Weinrich MC, McGregor AR, Diat F (1991) Demographic, Social and clinical correlates of Raynaud phenomenon. Int J Epidemiol 21:221-224
7. Silman A, Holligan S, Brennan P, Maddison P (1990) Prevalence of symptoms of Raynaud's phenomenon in general practice. BMJ 301:590-592
8. Riera G, Vilardell M, Vaque J, Fonollosa V, Bermejo B (1993) Prevalence of Raynaud's phenomenon in a healthy Spanish population. J Rheumatol 20:66-69
9. Choi WS, Ock SM, Byeon JH (2003) The Prevalence of Diagnosis as Raynaud's disease among the People complaint of abnormal sensation on hands and feet. J Korean Acad Fam Med 24:1085-1089
10. Thompson AE, Pope JE (2005) Calcium channel blockers for primary Raynaud's phenomenon: A meta-analysis. Rheumatol 44:145-150
11. Kim CM, Ock SM, Chung JH, Jang HS, Yoo DJ, Lee JB, Choi WS (2007) Recognition of family practitioners on cold hands/feet syndrome and Raynaud's disease. J Korean Acad Fam Med 28:339-345
12. Pittler MH, Ernst E (2000) Ginkgo biloba extract for the treatment of intermittent claudication: A meta-analysis of randomized trials. Am J Med 108:276-281
13. Maricq HR, Winrich MC (1988) Diagnosis of Raynaud's phenomenon assisted by color charts. J Rheumatol 15:454-459
14. WHOQOL-Group (1993) Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual Life Res 2:153-159
15. Min SK, Kim KI, Lee CI, Jung YC, Suh SY, Kim DK (2002) Development of the Korean versions of WHO Quality of Life scale and WHOQOL-BREF. Qual Life Res 11:593-600
16. Thompson SE, Shea B, Welch V, Fenlon D, Pope JE (2001) Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 44:1841-1847
17. Rademaker M, Cooke ED, Almond NE (1989) Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: A double blind randomized study. BMJ 298:561-564
18. Dziadzio M, Denton CP, Smith R, Howel K, Blann A, Bowers E (1999) Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week. Randomized, parallel-group, controlled trial. Arthritis Rheum 42:2646-2655
19. Coleiro B, Marshall SE, Denton CP (2001) Treatment of Raynaud's phenomenon with selective serotonin reuptake inhibitor fluoxetine. Rheumatology 40:1038-1043
20. Watson HR, Robb R, Belcher JJ (1992) Seasonal variation of Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol 26:1734-1737
21. Block JA, Sequeira W (2001) Raynaud's phenomenon. Lancet 357:2042-2048
22. Creager MA, Dzau VJ (2001) Raynaud's phenomenon; Harrison's principles of internal medicine, 15th edn. McGraw-Hill, New York, pp 1438-1439
23. Freeman RR, Meyes MD (1996) Familial aggregation of primary Raynaud's disease. Arthritis Rheum 39:1189-1191
24. National Institutes of Health (1993) Facts about Raynaud's phenomenon. National Heart, Lung and Blood Institute, National Institute of Health, Public Health Service, US Department of Health and Human Services, Bethesda Publication No. 93-2263
25. Sarkozi J, Bookman A, Mahon W, Ransay C, Detsky AS, Keystone EC (1986) nifedipine in the treatment of idiopathic Raynaud's syndrome. J Rheumatol 13:331-336
26. Raynaud's Treatment Study Investigators (2000) Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med 160:1101-1108